Vinorelbine/docetaxel combination treatment of metastatic breast cancer: A phase I study

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 3, 2007, Pages 365-373

  Bonneterre, J ^a   Campone, M ^b   Koralewski, P ^c   Blasinska Morawiec, M ^d   Deporte Fety, R ^b   Chatelut, E ^e   Leger, F ^f   Longerey, B ^f   Ecochard, L ^f   Douville, I ^f  

^a CENTRE OSCAR LAMBRET   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c Ludwik Rydygier Speciality Hospital in Krakow   (Poland)

^d M Kopernik Hospital   (Poland)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Docetaxel; Metastatic breast cancer; Oral vinorelbine; Phase I; Recommended dose

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BILIRUBIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADJUVANT THERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG HALF LIFE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SENSORY DYSFUNCTION; SIDE EFFECT; STENOSIS; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLAND; TAXOIDS; VINBLASTINE;

EID: 34250642403     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0375-6     Document Type: Article

References (33)

1. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer. A phase II trial of the Clinical Screening Cooperative Group of the EORTC. J Clin Oncol 13:314-322
2. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti K, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1424
3. Chan S, Friedrichs K, Noel D, Pinter T, Van belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, Von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha RG, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354
4. Ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M (1994) A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527-532
5. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Gaudier MJ, Chollet P, Lecourt L, Montcuquet P (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252
6. Garcia Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A, Martinez A, Pezous N, Delgado FM, Diaz Rubio E (1994) Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5:854-857
7. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L, Amato S, Barbieri R, Sabatini C, Leone BA (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12:336-341
8. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:2722-2730
9. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernandez O, Otero J, Kesselring G, Noguera C, Delgado G, Gaubert P, Delgado FM, Solidoro A (1995) Phase II trial of weekly i.v. vinorelbine as single agent in first-line advanced breast cancer chemotherapy: the Latin-American experience. Am J Clin Oncol 18:392-396
10. Twelves CJ, Dobbs NA, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, Canney P, Rubens RD (1994) A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70:990-993
11. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moloterni A, Zambetti M, Caraceni A, Martini C, Bonadonna G (1996) Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer: results from a phase II study. Breast Cancer Res Treat 39:285-291
12. R in advanced breast cancer. Semin Oncol 16:33-36
13. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649
14. Bissery MC, Vrignaud P, Lavelle F (1995) Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 22:3-16
15. Fumoleau P, Fety R, Delecroix V, Perrocheau G, Azli N (1997) Docetaxel combined with vinorelbine phase I results and new study designs. Oncology 11:29-31
16. Fumoleau P, Delacroix V, Perrocheau G, Borg-Olivier O, Maugard C, Fety R, Vernillet L, Bruno R, Azli N, Riva A, Kerbrat P (1996) Final results of a phase I dose finding and pharmacokinetic (P.K.) study of docetaxel in combination with vinorelbine in metastatic breast cancer. Ann Oncol 7, abstract 606P
17. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 328:1323-1332
18. French Epirubicin Study Group (2000) Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 18:3115-3124
19. Gregory RK, Powles TJ, Chang JC, Ashley S (1997) A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 33:2194-2197
20. Baille P, Bruno R, Schellens JHM, Webster LK, Millward M, Verweij J, Montay G (1997) Optimal sampling for Bayesian estimation of docetaxel (taxotere) clearance. Clin Cancer Res 3:1535-1538
21. Variol P, Nguyen L, Tranchand B, Puozzo C (2002) A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467-476
22. Nguyen L, Tranchand B, Puozzo CVariol P (2002) Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53:459-468
23. Marti JL, Bueso P, Mayordomo JI, Isla MD, Saenz A, Escudero P, Murillo L, Filipovich E, Andres R Tres A (2001) Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines. Ann Oncol 12:1061-1065
24. Ibrahim N, Rahman Z, Valero V, Murray J, Frye D, Hortobagyi G (2002) Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. Cancer Invest 20:29-37
25. Pectasides D, Dimopoulos MA, Aravantinos G, Kalophonos HP, Papacostas P, Briasoulis E, Cogas E, Papadimitriou CH, Skarlos D, Kosmidis P, Fountzilas G (2001) First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. Anticancer Res 21:3575-3580
26. Rosing H, Lustig V, Van Warmerdam LJC, Huizing MT, Ten Bokkel Huinink WW, Schellens JHM, Rodenhuis S, Bult A, Beijnen JH (2000) Pharmacokinetics and metabolism of docetaxel administered as a 1-hour intravenous infusion. Cancer Chemother Pharmacol 45:213-218
27. Van Den Neste E, De Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M (2000) A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 6:64-71
28. Campone M, Fumoleau P, Delecroix V, Deporte-Fety R, Perrocheau G, Vernillet L, Borg-Olivier O, Louboutin JP, Bissery MC, Riva A, Azli N (2001) Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. Ann Oncol 12:909-918
29. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch D, Kovats E, Lang F, Schneeweiss B, Scheithauer W (2001) Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19:621-627
30. Rodriguez J, Calvo E, Cortes J, Santisteban M, Perez-Calvo J, Martinez-Monge R, Brugarolas A, Fernandez-Hidalgo O (2002) Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study. Breast Cancer Res Treat 76:47-56
31. Gomez-Bernal A, Cruz JJ, Garcia-Palomo A, Arizcun A, Pujol E, Diz E, Martin G, Fonseca E, Sanchez P, Rodriguez C, Del Barco E, Lopez Y (2003) Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer. Am J Clin Oncol 26:127-131
32. Vassilomanolakis M, Koumakis G, Drufakou S, Aperis G, Demiri M, Barbounis V, Missitzis J, Efremidis AP (2003) Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother Pharmacol 51:179-183
33. Savio G, Leonardi V, Alù M, Laudani A, Calabria C, Scianna C, Agostara B, Ascoli M (2004) Treatment of metastatic breast cancer (MBC) with vinorelbine and docetaxel. Ann Oncol 15, 48, abstract 181